Home › Keratoconus › NCT03115710
The K-Map Study, Global Prevalence of KC
Who can join
Ages 6 to 23 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Male or female, 6-23 years of age. * Subjects seen for a non-ophthalmic appointment * Provide signed and dated patient consent form (signed by parents / legal guardians). * Willing to comply with all study procedures and be available for the duration of the study Exclusion Criteria: * Patients with a preexisting ocular disease / condition * Pregnancy or breastfeeding
About the study
Keratoconus is a ocular disease classified under ectatic diseases which often results in bilateral and asymmetrical corneal distortion. It usually affects patients at young age and can cause severe visual loss.
The overall goal of this study is to assess the prevalence of keratoconus (KC) in children and adolescents in various regions of the world based on modern tomographic imaging methods, and to verify whether the occurrence rates reported from literature should be corrected. Our hypothesis is that the prevalence of the disease is much higher than that traditionally reported.
At each site, corneal tomography examinations (Pentacam) will be performed bilaterally in children and adolescents, who are not ill or with any ophthalmological symptom. The population to be studied will be composed of children and adolescents on medical visits for non-ophthalmologic reasons, aged between 6 and 20 years. Multiple cities, from different continents (North America, South America, Asia and Europe) will participate.
What is being tested
- Rotating Scheimpflug camera (Pentacam HR) (diagnostic test)
Sponsor: University Hospital, Geneva · Participants: 20,000 · Started: Dec 28, 2015
Contact the study team
- Farhad Hafezi, MDPhD · Phone: +41 44 741 81 81
Official record on ClinicalTrials.gov — NCT03115710
Locations in the U.S.
| California | USC Roski Eye Institute, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.